# Pfizer Inc. (PFE) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $28.45, market value $162.2 billion.

## Valuation
- **P/E (trailing): 37.4×** (5-yr avg 23.7×, 3-yr avg 33.0×). Pfizer Inc. trades at 37.4× trailing earnings, well above its own five-year average of 23.7×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 2.5×**. Each dollar of revenue is priced at 2.5×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 6.8%** (5-yr avg 8.0%). Free cash flow equals 6.8% of the market value, in line with its five-year average of 8.0%. Above 5% is generally attractive.
- **Earnings yield: 2.7%**. The inverse of the P/E: 2.7% of the price is earned each year.

## Profitability
- **Net margin: 12.4%**. 12.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 9.0%**. 9.0% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 2.1%**. Each dollar of assets produces 2.1% of profit.

## Growth
- **Revenue growth (1 yr): -1.6%** (3-yr -12.0%/yr, 5-yr 8.5%/yr). Revenue fell 1.6% over the last year, against 8.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -3.5%** (3-yr -37.1%/yr, 5-yr -3.6%/yr). Earnings per share fell 3.5%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): -29.6%/yr**. Free cash flow has compounded at -29.6% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.75**. Debt is 0.75 times equity, moderate leverage.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 6.05%** ($1.72 per share, trailing). Pfizer Inc. yields 6.05%, high enough to check carefully: yields this high often precede a cut.
- **Consecutive years of increases: 15**. 15 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 3.6%/yr** (1-yr 2.4%). The dividend has grown 3.6% a year over five years.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover Pfizer Inc.; the consensus is buy, with an average price target of $28.61 (+1% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 24.1%** (YTD 20.2%, 3-mo 11.2%). The shares are up 24.1% over twelve months including dividends.
- **From 52-week high: -2.6%** (20.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 0.30** (volatility 24%). Beta of 0.30 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PFE · Page: https://foliofundamentals.com/stocks/pfe

Not investment advice.